Formycon AG (ETR:FYB)
19.74
+0.06 (0.30%)
At close: Mar 6, 2026
Formycon AG Revenue
Formycon AG had revenue of 10.50M EUR in the quarter ending September 30, 2025, a decrease of -26.07%. This brings the company's revenue in the last twelve months to 48.07M, down -17.19% year-over-year. In the year 2024, Formycon AG had annual revenue of 69.67M, down -10.32%.
Revenue (ttm)
48.07M
Revenue Growth
-17.19%
P/S Ratio
7.25
Revenue / Employee
192.30K
Employees
245
Market Cap
348.70M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 69.67M | -8.02M | -10.32% |
| Dec 31, 2023 | 77.70M | 35.20M | 82.83% |
| Dec 31, 2022 | 42.50M | 5.88M | 16.07% |
| Dec 31, 2021 | 36.61M | 2.32M | 6.76% |
| Dec 31, 2020 | 34.30M | 1.14M | 3.43% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Bayer Aktiengesellschaft | 45.58B |
| Siemens Healthineers AG | 23.30B |
| Fresenius SE & Co. KGaA | 22.45B |
| Merck KGaA | 21.10B |
| Redcare Pharmacy NV | 2.94B |
| Gerresheimer AG | 2.25B |
| Medios AG | 2.01B |
| MEDICLIN Aktiengesellschaft | 793.91M |
Formycon AG News
- 3 days ago - EQS-Adhoc: Formycon AG publishes preliminary figures for the 2025 fiscal year - Wallstreet:Online
- 11 days ago - EQS-News: Formycon announces positive clinical data for Keytruda biosimilar candidate FYB206 (pembrolizumab) - Wallstreet:Online
- 25 days ago - EQS-News: Lotus Pharmaceutical becomes commercialization partner for Formycon's Keytruda biosimilar candidate FYB206 across major parts of the Asia-Pacific Region - Wallstreet:Online
- 7 weeks ago - EQS-DD: Formycon AG: Active Ownership Fund SICAV SIF SCS, sell - Wallstreet:Online
- 7 weeks ago - EQS-DD: Formycon AG: Active Ownership Fund SICAV SIF SCS, Verkauf • news - Onvista
- 2 months ago - EQS-News: FDA approves another interchangeable Ranibizumab Biosimilar, Nufymco – Strengthening US Presence with Zydus as Commercialization Partner - Wallstreet:Online
- 3 months ago - Formycon AG: Formycon and Zydus partner for exclusive licensing and supply agreement of FYB206, a biosimilar to Keytruda (Pembrolizumab), in the U.S. and Canada - Finanz Nachrichten
- 3 months ago - Formycon and Zydus partner for exclusive licensing and supply agreement of FYB206, a biosimilar to Keytruda (Pembrolizumab), in the U.S. and Canada - Wallstreet:Online